Pulmonary Hypertension Trial, Recruiting NCT07667673 Sponsor: Istanbul University - Cerrahpasa Condition: Pulmonary Hypertension
Back to Pulmonary Hypertension

Pulmonary Hypertension Trial, Recruiting

NCT07667673
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults who are 18 years of age or older
  • People who have been diagnosed with a specific type of high blood pressure in the lungs called Group 1 pulmonary arterial hypertension (PAH), based on recognised medical guidelines
  • People who are already being monitored or treated for PAH at the study centre
  • People who have had both a right heart catheterisation (a procedure to measure pressure in the heart and lungs) and a cardiac MRI scan, with both tests done within an appropriate time frame
  • People for whom complete medical, imaging, and heart pressure measurement records are available and can be reviewed
  • People who are willing to take part in the study and have signed a written consent form

Who may not be able to join:

  • People under 18 years of age
  • People whose lung blood pressure condition falls into a different category (Groups 2 through 5 pulmonary hypertension), rather than Group 1 PAH
  • People who have not had both a right heart catheterisation and a cardiac MRI scan within an appropriate time frame
  • People whose medical or imaging records are incomplete in a way that would prevent proper review and analysis
  • People for whom follow-up medical records are not available

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Aybüke Geylan, MD, Istanbul University Cerrahpasa Institute of Cardiology

Phone: +905061258579

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Istanbul University - Cerrahpasa
Registry
ClinicalTrials.gov
Start date
11 May 2026
Est. completion
1 February 2027

Where this trial is recruiting

Turkey (Türkiye)

Primary endpoints

Risk reclassification rate after incorporation of multimodality imaging-derived RV characteristics into established non-invasive PAH risk models

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov